Screening of Children in Household Contact With Adult TB Patients in Mbarara Hospital, Uganda
Launched by EPICENTRE · Dec 13, 2011
Trial Information
Current as of June 22, 2025
Completed
Keywords
ClinConnect Summary
Because children with tuberculosis (TB) are usually smear-negative and therefore less infectious, they are generally not considered a public health risk. Up to 70% of children living in the same household with an adult with infectious TB will become infected, and more than 20% of them will develop active TB disease, usually within 12 months. The individual risk of developing disease once infected is highest in children \<5 years. In addition, children under 5 years are at higher risk of developing disseminated forms of TB. The impact of childhood TB is worsened by co-infection with HIV. Con...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any child who has lived in the same household with the index case continuously for at least 2 weeks within the 3-month period immediately preceding the diagnosis of smear- positive or culture-positive TB in the index case.
- • Informed consent signed by the parent or legal guardian
- • Living within a 2-hour radius of Mbarara town
- Exclusion Criteria:
- • Child currently receiving anti-tuberculosis treatment
- • Child has received a full course of anti-TB treatment within the last 6 months
About Epicentre
Epicentre is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative study designs and rigorous scientific methodologies. With a focus on infectious diseases and public health, Epicentre leverages its extensive expertise in epidemiology and clinical operations to facilitate the development of effective interventions. Committed to ethical standards and regulatory compliance, Epicentre collaborates with global partners to ensure the successful execution of clinical trials, ultimately contributing to the enhancement of global health initiatives and the well-being of communities worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Julius Kiwanuka, MD
Principal Investigator
Mbarara University of Science and Technology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials